Innervace is a regenerative therapy company developing technology that acts as pre-formed, anatomically-inspired, implantable tissue pathways to directly replace lost connections due to brain degeneration or injury.
Our lead program mimics the lost nigrostriatal pathway in patients with Parkinson’s disease (PD).
Innervace’s innovative technology has the potential to be a disease modifying technology by directly replacing neuroanatomy lost to the progression of disease.
This strategy is in stark contrast to currently approved therapies that only temporarily manage symptoms.
The company is based upon technology developed at the University of Pennsylvania.
News
Innervace CEO Nader Halim, on World Parkinson's Day and his company's message to researchers and patients.
To view the complete Tuesday Talks episode with Innervace CEO Nader Halim, please visit wewillcure.com
Deerfield backs a Penn spinout aiming to shake up Parkinson's treatments using stem cells, brain surgery
Click here to read the full subscription-only article.
Innervace Secures Up to $40 Million to Advance Novel Regenerative Medicine Platform for Neurological Disorders
Series A financing round, led by Deerfield Management, to accelerate a new cell therapy modality for the treatment of neurological…
